The estimated Net Worth of Charles B O'keeffe is at least 14.9 百万$ dollars as of 15 February 2024. Mr. keeffe owns over 4,000 units of Catalyst Pharmaceuticals Inc stock worth over 13,344,189$ and over the last 18 years he sold CPRX stock worth over 1,411,279$. In addition, he makes 169,564$ as Lead Independent Director at Catalyst Pharmaceuticals Inc.
Sign up
Mr. Keeffe CPRX stock SEC Form 4 insiders trading
Charles has made over 53 trades of the Catalyst Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of CPRX stock worth 77,840$ on 15 February 2024.
The largest trade he's ever made was exercising 105,000 units of Catalyst Pharmaceuticals Inc stock on 2 October 2014 worth over 94,500$. On average, Charles trades about 11,729 units every 81 days since 2007. As of 15 February 2024 he still owns at least 685,724 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Mr. keeffe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles O'Keeffe biography
Charles B. O'Keeffe is Lead Independent Director of Catalyst Pharmaceutical Partners, Inc. Mr. O’Keeffe also served as a consultant to us from December 2004 until June 2011. Mr. O’Keeffe is a Professor in the Departments of Pharmacology, Epidemiology and Community Health at Virginia Commonwealth University (“VCU”), and has served in such capacity since January 1, 2004. Mr. O’Keeffe joined VCU after retiring as President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc., a position Mr. O’Keeffe held from 1991 until 2003. As President of Drug Abuse Rehabilitation Services (from 1970 until 1971), he developed the first child-resistant, abuse-resistant vehicle for dispensing methadone. He served as president of Washington Reference Laboratories from 1972 until 1975, which provided toxicology services to the Department of Defense during the Vietnam War. He has served in the White House (from 1970 until 1973 and from 1976 until 1980) for three presidents—as advisor, special assistant for international health and deputy director for international affairs in the Office of Drug Abuse Policy—and has served on U.S. delegations to the World Health Assembly and the U.N. Commission on Narcotic Drugs. The Board believes the characteristics that qualify Mr. O’Keeffe to serve as a member of our Board include his business leadership experience and his experience in the pharmaceutical industry.
What is the salary of Charles Keeffe?
As the Lead Independent Director of Catalyst Pharmaceuticals Inc, the total compensation of Charles Keeffe at Catalyst Pharmaceuticals Inc is 169,564$. There are 10 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of 3,371,560$.
How old is Charles Keeffe?
Charles Keeffe is 80, he's been the Lead Independent Director of Catalyst Pharmaceuticals Inc since 2011. There are no older and 16 younger executives at Catalyst Pharmaceuticals Inc.
What's Charles Keeffe's mailing address?
Charles's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, , CORAL GABLES, FL, 33134.
Insiders trading at Catalyst Pharmaceuticals Inc
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over 35,595,986$ worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth 7,307,159$ . The most active insiders traders include Pharmaceutical Inc Biomarin、Patrick J Mcenany、Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of 1,097,019$. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth 60,150$.
What does Catalyst Pharmaceuticals Inc do?
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
What does Catalyst Pharmaceuticals Inc's logo look like?
Complete history of Mr. keeffe stock trades at Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc executives and stock owners
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Patrick McEnany,
Chairman of the Board, President, Chief Executive Officer -
Steven Miller,
Chief Operating Officer, Chief Scientific Officer -
Gary Ingenito,
Chief Medical Officer and Head of Regulatory Affairs -
Patrick J. McEnany,
Co-Founder, Chairman, Pres & CEO -
Dr. Steven R. Miller,
COO & Chief Scientific Officer -
Dr. Gary Ingenito,
Chief Medical & Regulatory Officer -
Alicia Grande,
Chief Accounting Officer, VP, Treasurer & CFO -
Alicia Grande,
Chief Financial Officer, Vice President, Treasurer -
Jeffrey Del Carmen,
Chief Commercial Officer -
Brian Elsbernd,
Chief Compliance Officer, Chief Legal Officer -
Charles O'Keeffe,
Lead Independent Director -
Donald Denkhaus,
Independent Director -
David Tierney,
Independent Director -
Richard Daly,
Independent Director -
Jeffrey Del Carmen,
Chief Commercial Officer -
Philip B. Schwartz,
Corp. Sec. -
Dr. Preethi Sundaram Ph.D.,
Chief Product Devel. Officer -
Pete Curry Sr.,
VP of Sales -
Brian Elsbernd J.D.,
Chief Compliance Officer & Chief Legal Officer -
Mary Coleman,
VP & Head of Investor Relations -
Philip H Coelho,
Director -
Paul J Merrigan,
Chief Commercial Officer -
M Douglas Winship,
V.P. of Regulatory Operations -
Daniel Brennan,
Chief Commercial Officer -
Tamar Thompson,
Director -
David D Muth,
Exec. V.P., Corp. Development -
Hubert E Md Huckel,
Director -
Milton J Wallace,
Director -
Pharmaceutical Inc Biomarin,
10% owner -
Jack Weinstein,
V.P., Treasurer & CFO -
Molly Harper,
Director -
Preethi Sundaram,
Chief Strategy Officer -
Steve Miller,
Chief Op. & Scientific Officer